Inconsistent Phase III efficacy results for Bayer HealthCare Pharmaceuticals AG's inhalable ciprofloxacin in treating bronchiectasis, coupled with uncertainties about long-term benefit and antimicrobial resistance, proved too troubling for the majority of US FDA advisory committee members Nov. 16.
The Antimicrobial Drugs Advisory Committee narrowly voted that Bayer had not demonstrated substantial evidence of efficacy and safety for a...